Applied BioCode Corp (ABC, 瑞磁生技) expects that the emergency use authorization it has obtained from the US Food and Drug Administration (FDA) for a COVID-19 test kit would spur revenue growth next year, the firm said yesterday. The kit, which tests for COVID-19 and flu, has been supplied to more than 10 hospitals in the US, it said. The new product would generate a rise in revenue next month at the earliest, ABC vice president Nick Chen (陳祐寧) told the Taipei Times by telephone. While conventional polymerase chain reaction test kits can test for up to three viruses, ABC’s “CoV-2 Flu Plus